Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Corcept Therapeutics Incorporated, AstraZeneca PLC or AstraZeneca PLC because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Corcept Therapeutics Incorporated, AstraZeneca PLC and AstraZeneca PLC compare based on key financial metrics to determine which better meets your investment needs.

About Corcept Therapeutics Incorporated, AstraZeneca PLC and AstraZeneca PLC

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig’s disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Latest Pharmaceuticals and Corcept Therapeutics Incorporated, AstraZeneca PLC Stock News

As of August 13, 2026, Corcept Therapeutics Incorporated had a $11.9 billion market capitalization, compared to the Pharmaceuticals median of $634.5 million. Corcept Therapeutics Incorporated’s stock is up 224.6% in 2026, up 2% in the previous five trading days and up 50.17% in the past year.

Currently, Corcept Therapeutics Incorporated’s price-earnings ratio is 243.4. Corcept Therapeutics Incorporated’s trailing 12-month revenue is $830.8 million with a 6.6% net profit margin. Year-over-year quarterly sales growth most recently was 31.7%. Analysts expect adjusted earnings to reach $2.133 per share for the current fiscal year. Corcept Therapeutics Incorporated does not currently pay a dividend.

As of August 13, 2026, AstraZeneca PLC had a $245.2 billion market cap, putting it in the 99th percentile of all stocks. AstraZeneca PLC’s stock is up 69.2% in 2026, down 3.6% in the previous five trading days and up 7.02% in the past year.

Currently, AstraZeneca PLC’s price-earnings ratio is 23.5. AstraZeneca PLC’s trailing 12-month revenue is $61.4 billion with a 17.0% net profit margin. Year-over-year quarterly sales growth most recently was 6.4%. Analysts expect adjusted earnings to reach $10.085 per share for the current fiscal year. AstraZeneca PLC currently has a 1.5% dividend yield.

How We Compare Corcept Therapeutics Incorporated, AstraZeneca PLC and AstraZeneca PLC Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Corcept Therapeutics Incorporated, AstraZeneca PLC and AstraZeneca PLC’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Corcept Therapeutics Incorporated, AstraZeneca PLC and AstraZeneca PLC Stock Value Grades

Company	Ticker	Value
Corcept Therapeutics Incorporated	CORT	F
AstraZeneca PLC	AZN	D
AstraZeneca PLC	AZN	D

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Corcept Therapeutics Incorporated has a Value Score of 3, which is Ultra Expensive. AstraZeneca PLC has a Value Score of 27, which is Expensive. AstraZeneca PLC has a Value Score of 27, which is Expensive.

The Value Stock Winner: No Clear Winner

Neither Corcept Therapeutics Incorporated, AstraZeneca PLC or AstraZeneca PLC has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Corcept Therapeutics Incorporated, AstraZeneca PLC or AstraZeneca PLC is the better investment when it comes to value.

Corcept Therapeutics Incorporated, AstraZeneca PLC and AstraZeneca PLC’s Momentum Grades

Company	Ticker	Momentum
Corcept Therapeutics Incorporated	CORT	A
AstraZeneca PLC	AZN	D
AstraZeneca PLC	AZN	D

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Corcept Therapeutics Incorporated has a Momentum Score of 96, which is Very Strong. AstraZeneca PLC has a Momentum Score of 36, which is Weak. AstraZeneca PLC has a Momentum Score of 36, which is Weak.

The Momentum Grade Winner: Corcept Therapeutics Incorporated

As you can clearly see from the Momentum Grade breakdown above, Corcept Therapeutics Incorporated is considered to have stronger momentum compared to AstraZeneca PLC. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Corcept Therapeutics Incorporated could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Corcept Therapeutics Incorporated, AstraZeneca PLC and AstraZeneca PLC’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Corcept Therapeutics Incorporated	CORT	B
AstraZeneca PLC	AZN	C
AstraZeneca PLC	AZN	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Corcept Therapeutics Incorporated has a Earnings Estimate Score of 78, which is Positive. AstraZeneca PLC has a Earnings Estimate Score of 47, which is Neutral. AstraZeneca PLC has a Earnings Estimate Score of 47, which is Neutral.

The Earnings Estimate Revisions Grade Winner: Corcept Therapeutics Incorporated

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Corcept Therapeutics Incorporated has a better Earnings Estimate Revisions Grade than AstraZeneca PLC. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Corcept Therapeutics Incorporated could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Corcept Therapeutics Incorporated, AstraZeneca PLC and AstraZeneca PLC Grades

In addition to Estimate Revisions, Value and Momentum, A+ Investor also provides grades for Growth and Quality.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Corcept Therapeutics Incorporated, AstraZeneca PLC and AstraZeneca PLC pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Corcept Therapeutics Incorporated, AstraZeneca PLC or AstraZeneca PLC Stock?

Overall, Corcept Therapeutics Incorporated stock has a Value Score of 3, Momentum Score of 96 and Estimate Revisions Score of 78.

AstraZeneca PLC stock has a Value Score of 27, Momentum Score of 36 and Estimate Revisions Score of 47.

AstraZeneca PLC stock has a Value Score of 27, Momentum Score of 36 and Estimate Revisions Score of 47.

Comparing Corcept Therapeutics Incorporated, AstraZeneca PLC and AstraZeneca PLC’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.